Related Experiment Video
Updated: Jun 8, 2025

Assessing Changes in Volatile General Anesthetic Sensitivity of Mice after Local or Systemic Pharmacological Intervention
Published on: October 16, 2013
Optimizing Pediatric Sedation: Evaluating Remimazolam and Dexmedetomidine for Safety and Efficacy in Clinical
Vera Scheckenbach1, Frank Fideler2
1Department of Anesthesiology and Intensive Care Medicine, University Hospital Tübingen, Eberhard Karls University Tübingen, Hoppe-Seyler Str. 3, 72076, Tübingen, Germany. Vera.Scheckenbach@med.uni-tuebingen.de.
Insights
Remimazolam (RMZ) and dexmedetomidine (DEX) show promise for safer pediatric sedation due to favorable pharmacokinetics and fewer side effects. Further research is needed to fully evaluate their risks in children.
Area of Science:
- Pediatric Anesthesiology
- Pharmacology
- Critical Care Medicine
Background:
- Pediatric sedation and anesthesia carry risks of life-threatening events due to children's vulnerability.
- Current sedation methods necessitate improvements in safety and reduced adverse events.
- There is a need for sedatives with fewer intrinsic side effects for pediatric use.
Purpose of the Study:
- To evaluate remimazolam (RMZ) and dexmedetomidine (DEX) as potential ideal sedatives for pediatric patients.
- To compare the pharmacokinetic properties and safety profiles of RMZ and DEX in children.
- To assess the suitability of RMZ and DEX for reducing sedation-related complications in pediatric procedures.
Main Methods:
- Pharmacokinetic evaluation of remimazolam (RMZ) and dexmedetomidine (DEX).
- Review of existing literature on the use of RMZ and DEX in pediatric medicine.
- Comparison of drug metabolism, elimination, and potential for accumulation.
Main Results:
- Remimazolam (RMZ) is an ultrashort-acting benzodiazepine with rapid metabolism and minimal accumulation, reversible with flumazenil.
- Dexmedetomidine (DEX) is an alpha-2 agonist offering coanalgesia, arousal sedation, and a favorable cardiorespiratory profile.
- Both RMZ and DEX show potential in delirium prevention/treatment, with DEX offering neuroprotection.
Conclusions:
- Remimazolam (RMZ) and dexmedetomidine (DEX) possess characteristics of optimal pediatric sedatives, including minimal side effects and broad dosage ranges.
- These agents may reduce the incidence of sedation-related life-threatening events in children.
- Further clinical research is essential to comprehensively assess the risks and benefits of RMZ and DEX in pediatric populations.
Abstract:
Daily, children undergo countless investigations and interventions, which require sedation and immobilization to ensure safety and accuracy. This remains associated with a persistent risk of sedation-induced life-threatening events as children are particularly vulnerable to adverse medical events and complications. Consequently, there is an urgent need to increase the safety of pediatric sedation and anesthesia. An ideal approach involves the use of drugs with fewer intrinsic side effects. In this context, on the basis of their pharmacokinetic properties, remimazolam (RMZ) and dexmedetomidine (DEX) were evaluated for their suitability as ideal sedatives. RMZ and DEX, both of which are currently available in pediatric medicine, have shown great promise in initial publications. To date, only very limited data concerning RMZ in small children are available. RMZ is a novel, ultrashort-acting benzodiazepine that is metabolized by tissue esterase, largely independent of organ function. It has a context-sensitive half-life of approximately 10 min, with minimal accumulation even with prolonged use. Its effects can be completely reversed with flumazenil. DEX, an isomer of medetomidine, is a potent α2-receptor-agonist with multiple indications in anesthesia and intensive care medicine. It has coanalgesic potential, allows for 'arousal sedations' and has a low profile for cardiorespiratory side effects. DEX is metabolized in the liver and is predominantly excreted renally. Both drugs show potential in the prevention and treatment of delirium, with DEX having additional neuroprotective effects. DEX and RMZ possess several properties of an optimal sedative, including clinically insignificant main metabolites and a broad dosage range, indicating their potential to reduce the incidence of sedation-related life-threatening events in children. However, further clinical research is necessary to better evaluate their potential risks.
More Related Videos
Related Concept Videos
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Parenteral Anesthetics: Overview
Sedatives and Hypnotics Drugs: Benzodiazepines
Benzodiazepines work by enhancing the effects of the inhibitory neurotransmitter GABA. They bind to the GABAA receptor, increasing its affinity for GABA, which opens chloride...
Sedatives and Hypnotics: Overview
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
Inhalational Anesthetics: Overview
Skeletal Muscle Relaxants: Adverse Effects
Unlike...

